Amylin agonists: A novel approach in the treatment of diabetes

Diabetes

Volumn 53, Issue SUPPL. 3, 2004, Pages

  Schmitz, Ole ^a   Brock, Birgitte ^b   Rungby, Jorgen ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLIN AGONIST; AMYLOID; ANTIDIABETIC AGENT; GLUCAGON; INSULIN; PLACEBO; PRAMLINTIDE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONFERENCE PAPER; DIABETES CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GLUCAGON RELEASE; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PHARMACODYNAMICS; PRIORITY JOURNAL;

AMYLOID; ANIMALS; CLINICAL TRIALS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN;

EID: 9444257636     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.suppl_3.S233     Document Type: Conference Paper

References (67)

1. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Prager R: Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34:52-54, 1991
2. Nishi M, Sanke T, Seino S, Eddy RL, Fan YS, Byers MG, Shows TB, Bell GI, Steiner DF: Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history. Mol Endocrinol 3:1775-1781, 1989
3. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, Solari R, Lee MG, Foord SM: RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:333-339, 1998
4. Muff R, Buhlmann N, Fischer JA, Born W: An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3. Endocrinology 140:2924-2927, 1999
5. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 27 (Suppl. 1):S15-S35, 2004
6. Vilsboll T, Holst JJ: Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia. 47:357-366, 2004
7. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84:8628-8632, 1987
8. Westermark P, Wernstedt C, O'Brien TD, Hayden DW, Johnson KH: Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol 127:414-417, 1987
9. Koda J, Fineman M, Kolterman O: 24-hour plasma amylin profiles are elevated in IGT subjects vs. normal controls (Abstract). Diabetes 44 (Suppl. 2):A238, 1995
10. Juhl CB, Porksen N, Sturis J, Hansen AP, Veldhuis JD, Pincus S, Fineman M, Schmitz O: High-frequency oscillations in circulating amylin concentrations in healthy humans. Am J Physiol Endocrinol Metab 278:E484-E490, 2000
11. Nyholm B, Fineman MS, Koda JE, Schmitz O: Plasma amylin immunoreactivity and insulin resistance in insulin resistant relatives of patients with non-insulin-dependent diabetes mellitus. Horm Metab Res 30:206-212, 1998
12. Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhausl W, Prager R: Role of islet amyloid polypeptide secretion in insulin-resistant humans. Diabetologia 37:188-194, 1994
13. Hoppener JW, Ahren B, Lips CJ: Islet amyloid and type 2 diabetes mellitus. N Engl J Med 343:411-419, 2000
14. Hull RL, Westermark GT, Westermark P, Kahn SE: Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 89:3629-3643, 2004
15. Castillo MJ, Scheen AJ, Lefebvre PJ: Amylin/islet amyloid polypeptide: biochemistry, physiology, pathophysiology. Diabete Metab 21:3-25, 1995
16. Wang ZL, Bennet WM, Ghatei MA, Byfield PG, Smith DM, Bloom SR: Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes 42:330-335, 1993
17. Martinez A, Kapas S, Miller MJ, Ward Y, Cuttitta F: Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic β-cells. Endocrinology 141:406-411, 2000
18. Gedulin BR, Rink TJ, Young AA: Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46:67-70, 1997
19. Gedulin BR, Jodka C, Green D: Amylin inhibition of arginine-induced glucagon secretion: comparison with glucagon-like peptide-1 (7-36)-amide (GLP-1) (Abstract). Diabetologia 39 (Suppl.):A154, 1996
20. Silvestre RA, Rodriguez-Gallardo J, Jodka C, Parkes DG, Pittner RA, Young AA, Marco J: Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas. Am J Physiol Endocrinol Metab 280:E443-E449, 2001
21. Macdonald IA: Amylin and the gastrointestinal tract. Diabet Med 14 (Suppl. 2):S24-S28, 1997
22. Young AA, Gedulin BR, Rink TJ: Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 45:1-3, 1996
23. Young AA, Gedulin B, Vine W, Percy A, Rink TJ: Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38:642-648, 1995
24. Jodka C, Green D, Young A: Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve (Abstract). Diabetes 45 (Suppl. 2):A235, 1996
25. Gedulin BR, Young AA: Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats. Diabetes 47:93-97, 1998
26. Morley JE, Flood JF, Farr SA, Perry HJ, III, Kaiser FE, Morley PM: Effects of amylin on appetite regulation and memory. Can J Physiol Pharmacol 73:1042-1046, 1995
27. Lutz TA, Del Prete E, Scharrer E: Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol Behav 55:891-895, 1994
28. Lutz TA, Del Prete E, Scharrer E: Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides 16:457-462, 1995
29. Beaumont K, Kenney MA, Young AA, Rink TJ: High affinity amylin binding sites in rat brain. Mol Pharmacol 44:493-497, 1993
30. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K: In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62:553-567, 1994
31. Rogers RC, McTigue DM, Hermann GE: Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Neurosci Biobehav Rev 20:57-66, 1996
32. Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Bloom SR: Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia 33:115-117, 1990
33. Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Macrae AD, Bloom SR: Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab 74:1032-1035, 1992
34. Wilding JP, Khandan-Nia N, Bennet WM, Gilbey SG, Beacham J, Ghatei MA, Bloom SR: Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinaemic euglycaemic clamp in humans. Diabetologia 37:166-169, 1994
35. Zierath JR, Galuska D, Engstrom A, Johnson KH, Betsholtz C, Westermark P, Wallberg-Henriksson H: Human islet amyloid polypeptide at pharmacological levels inhibits insulin and phorbol ester-stimulated glucose transport in in vitro incubated human muscle strips. Diabetologia 35:26-31, 1992
36. Goldsbury CS, Cooper GJ, Goldie KN, Muller SA, Saafi EL, Gruijters WT, Misur MP, Engel A, Aebi U, Kistler J: Polymorphic fibrillar assembly of human amylin. J Struct Biol 119:17-27, 1997
37. Westermark P, Engstrom TJ, Johnson KH, Westermark GT, Betsholtz C: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 87:5036-5040, 1990
38. Jaikaran ET, Higham CE, Serpell LC, Zurdo J, Gross M, Clark A, Fraser PE: Identification of a novel human islet amyloid polypeptide beta-sheet domain and factors influencing fibrillogenesis. J Mol Biol 308:515-525, 2001
39. Colburn WA, Gottlieb AB, Koda J, Kolterman OG: Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J Clin Pharmacol 36:13-24, 1996
40. Young AA, Vine W, Gedulin B: Preclinical pharmacology of pramlintide in the rat: comparison with human and rat amylin. Drug Dev Res 37:231-248, 1996
41. Sakurai H, Dobbs RE, Unger RH: The role of glucagon in the pathogenesis of the endogenous hyperglycemia of diabetes mellitus. Metabolism, 24: 1287-1297, 1975
42. American Diabetes Association: Postprandial blood glucose. Diabetes Care 24 (Suppl. 1):775-778, 2001
43. Kolterman OG, Gottlieb A, Moyses C, Colburn W: Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care 18:1179-1182, 1995
44. Kong MF, King P, Macdonald IA, Stubbs TA, Perkins AC, Blackshaw PE, Moyses C, Tattersall RB: Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 40:82-88, 1997
45. Thompson RG, Gottlieb A, Organ K, Koda J, Kisicki J, Kolterman OG: Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes. Diabet Med 14:547-555, 1997
46. Nyholm B, Moller N, Gravholt CH, Orskov L, Mengel A, Bryan G, Moyses C, Alberti KG, Schmilz O: Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:1083-1089, 1996
47. Mather KJ, Paradisi G, Learning R, Hook G, Steinberg HO, Fineberg N, Hanley R, Baron AD: Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. Diabetes Metab Res Rev 18:118-126, 2002
48. Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A: Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. Diabetologia 39:492-499, 1996
49. Thompson RG, Peterson J, Gottlieb A, Mullane J: Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes 46:632-636, 1997
50. Thompson RG, Pearson L, Kolterman OG: Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. Diabetologia 40:1278-1285, 1997
51. Nyholm B, Orskov L, Hove KY, Gravholt CH, Moller N, Alberti KG, Moyses C, Kolterman O, Schmitz O: The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 48:935-941, 1999
52. Young AA, Crocker LB, Wolfe-Lopez D, Cooper GJ: Daily amylin replacement reverses hepatic glycogen depletion in insulin-treated streptozotocin diabetic rats. FEBS Lett 287:203-205, 1991
53. Orskov L, Nyholm B, Yde HK, Gravholt CH, Moller N, Schmitz O: Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in type 1 diabetic subjects. Diabet Med 16:867-874, 1999
54. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, Maggs DG, Kolterman OG, Chandran M, Mudaliar SR, Henry RR: Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 26:1-8, 2003
55. Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG: Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. Diabetes Care 26:3074-3079, 2003
56. Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG: The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 51:636-641, 2002
57. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG: The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 34:504-508, 2002
58. Ludvik B, Thomaseth K, Nolan JJ, Clodi M, Prager R, Pacini G: Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects. Eur J Clin Invest 33:316-322, 2003
59. Dinneen S, Alzaid A, Turk D, Rizza R: Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38:337-343, 1995
60. Dinneen S, Gerich J, Rizza R: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N Engl J Med 327:707-713, 1992
61. Baron AD, Schaeffer L, Shragg P, Kolterman OG: Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36:274-283, 1987
62. Ahren B, Adner N, Svartberg J, Petrella E, Holst JJ, Gutniak MK: Antidiabetogenic effect of the human amylin analogue, pramlintide, in type 1 diabetes is not mediated by GLP-1. Diabet Med 19:790-792, 2002
63. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG: A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25:724-730, 2002
64. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26:784-790, 2003
65. Hollander P, Ratner R, Fineman M, Strobel S, Shen L, Maggs D, Kolterman O, Weyer C; Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab 5:408-414, 2003
66. Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C: Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 12:661-668, 2004
67. Moller DE: New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414:821-827, 2001